Lyell Immunopharma (LYEL) risk factors, FY2024 10-K

Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital

1. 01We are a clinical-stage biopharmaceutical company that has incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing net losses for the foreseeable future
2. 02We operate in a rapidly evolving field and have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability
3. 03We currently have no products approved for sale and have never generated revenue from product sales. We may never generate revenue from product sales or achieve profitability
4. 04We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts
5. 05our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates
6. 06We have long-lived assets, which are assessed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. In addition, we may never realize the full value of our long‑lived assets, causing us to record material impairment charges

Risks Related to Our Business and Industry

1. 07If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed
2. 08we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations
3. 09We are highly dependent on our key personnel and, if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
4. 10If we cannot maintain our company culture as we grow, our success and our business may be harmed
5. 11Any litigation or adversarial proceedings could be costly and time-consuming to defend
6. 12We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us
7. 13Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
8. 14Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations

Risks Related to Manufacturing

1. 15The manufacturing of cellular therapies is very complex. We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs, delay our programs or limit supply of our product candidates
2. 16require regulatory approval before selling any products manufactured at that facility. Such an event could substantially delay our clinical trials or commercialization of our product candidates
3. 17We may rely on third parties to manufacture our product candidates, which subjects us to risks and could delay or prevent our development and/or commercialization, if approved, of our product candidates
4. 18Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all

Risks Related to Our Dependence on Third Parties

1. 19We have in the past, and we may in the future, form or seek collaborations or strategic alliances or enter into additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements
2. 20We recently acquired ImmPACT and may not realize the benefits of such acquisition or any potential future collaborations, licenses, product acquisitions or other strategic transactions
3. 21We may not be able to successfully integrate ImmPACT into our business, including manufacturing of IMPT-314 at LyFE, or to realize the anticipated benefits of the acquisition
4. 22Additionally, general market and economic conditions or governmental actions generally may inhibit our successful integration of ImmPACT
5. 23Failure to successfully address these and other issues related to the acquisition could have a material adverse effect on our financial condition and results of operations and could adversely affect our ability to successfully implement our business strategy
6. 24Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites
7. 25We face substantial competition in rapidly changing industries, which may result in others discovering, developing or commercializing products before or more successfully than we do

Risks Related to Regulation and Legal Compliance

1. 26We are in the first phase of clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates and any product candidates we acquire
2. 27Our cellular therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates
3. 28Clinical development involves a lengthy and expensive process with an uncertain outcome
4. 29Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data
5. 30The FDA and comparable foreign regulatory approval processes are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approvals of our product candidates, our business will be substantially harmed
6. 31We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
7. 32IMPT-314 has received Fast Track designation from the FDA, but receipt of such designation or any other designation, such as Regenerative Medicine Advanced Therapy designation, may not actually lead to a faster development, regulatory review or approval process, and does not assure ultimate FDA approval
8. 33We may be subject to applicable fraud and abuse, including anti-kickback and false claims, transparency, health information privacy and security and other healthcare laws. Failure to comply with such laws, may result in substantial penalties
9. 34Changes in healthcare policies, laws and regulations may impact our ability to obtain approval for, or commercialize our product candidates, if approved
10. 35sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions
11. 36Outside the United States, an increasing number of laws, regulations and industry standards may govern data privacy and security. For example, the EU GDPR and the UK GDPR impose strict requirements for processing personal data
12. 37International expansion of our business would expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States

Risks Relating to Our Intellectual Property

1. 38If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected
2. 39The lifespans of our patents may not be sufficient to effectively protect our products and business
3. 40We may not be able to protect our intellectual property rights throughout the world
4. 41initiate, and even if we or our licensors are successful, the damages or other remedies awarded, if any, may not be commercially meaningful
5. 42If we are sued for infringing or misappropriating the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts
6. 43We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third-party’s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates
7. 44We have in-licensed a portion of our intellectual property from our partners and other third parties. If we breach any of our license agreements with these licensors, we could potentially lose the ability to continue the development and potential commercialization of one or more of our product candidates
8. 45We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties
9. 46candidates and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities
10. 47We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business
11. 48We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 49If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be adversely affected and our business could be harmed
13. 50We may be subject to claims that our employees, consultants or independent contractors have breached non-compete or non-solicit obligations and/or wrongfully used or disclosed confidential information of third parties

Risks Related to Ownership of Our Common Stock

1. 51Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock
2. 52Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
3. 53The market price of our common stock has been, and may continue to be, volatile, which could result in substantial losses for investors
4. 54We may be unable to comply with the applicable continued listing requirements of The Nasdaq Global Select Market
5. 55If securities or industry analysts do not publish research or reports about our business, or if they publish negative or neutral evaluations of our stock, the price of our stock could decline
6. 56Sales of a substantial number of shares of our common stock by our existing stockholders could cause the price of our common stock to decline
7. 57Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or our products
8. 58Future acquisitions, strategic investments, partnerships or alliances could be difficult to identify and integrate, divert the attention of management, disrupt our business, dilute stockholder value and adversely affect our operating results and financial condition
9. 59The requirements of being a public company require our management to devote substantial time to compliance initiatives and corporate governance practices and could divert management’s attention and strain our resources
10. 60Changes in tax laws or regulations, including those that are applied adversely to us or our customers, may have a material adverse effect on our business, cash flow, financial condition, results of operations, effective tax rate or compliance costs
11. 61Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
12. 62Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection and other losses